期刊
BMC OPHTHALMOLOGY
卷 22, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s12886-022-02325-x
关键词
Diabetic macular edema; Anti-VEGF; Insulin; Visual acuity; Central macular thickness
资金
- Tasmanian Community Fund
- National Health and Medical Research Council (NHMRC) Australia Centre for Research Excellence [GNT1116360]
- Diabetes Tasmania
- Patricia F Gordon Postgraduate Top-Up Scholarship in Medical Research
- Cancer Council Tasmania/College of Health and Medicine, University of Tasmania Fellowship
- NHMRC Senior Research Fellowship
The study found that insulin therapy does not affect the effectiveness of anti-VEGF injection treatment for diabetic macular edema.
Objectives To assess whether insulin therapy impacts the effectiveness of anti-vascular endothelial growth factor (anti-VEGF) injection for the treatment of diabetic macular edema (DME) in type 2 diabetes mellitus. Methods This was a retrospective multi-center analysis. The best-corrected visual acuity (BCVA) at 12 months, BCVA change, central macular thickness (CMT), CMT change, and cumulative injection number were compared between the insulin and the oral hypoglycemic agent (OHA) groups. Results The mean final BCVA and CMT improved in both the insulin (N = 137; p < 0.001; p < 0.001, respectively) and the OHA group (N = 61; p = 0.199; p < 0.001, respectively). The two treatment groups were comparable for final BCVA (p = 0.263), BCVA change (p = 0.184), final CMT (p = 0.741), CMT change (p = 0.458), and the cumulative injections received (p = 0.594). The results were comparable between the two groups when stratified by baseline vision (p > 0.05) and baseline HbA1c (p > 0.05). Conclusion Insulin therapy does not alter treatment outcomes for anti-VEGF therapy in DME.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据